September 2, 2025 — Leads & Copy — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) CEO David Stamler will deliver a corporate update at the Biotech Showcase hosted by Peak Asset Management and Monsoon Communications. The presentation is scheduled for Wednesday, Sept. 3, 2025, in Australia and Tuesday, Sept. 2, 2025, in the United States.
Webcast details:
AUSTRALIA PARTICIPANTS:
Date: Wednesday, 3 September 2025
Time: 12:35 p.m. AEST (Sydney/Melbourne)
UNITED STATES PARTICIPANTS:
Date: Tuesday, 2 September 2025
Time: 7:35 p.m. Pacific Time, 10:35 p.m. Eastern Time
Register for the Zoom webcast: https://us06web.zoom.us/webinar/register/WN_ocDL721LTS6_R4B-DG63Kw
Alterity Therapeutics is focused on developing therapies for neurodegenerative diseases, initially targeting Parkinson’s disease and related disorders. Its lead asset, ATH434, has shown clinically meaningful efficacy in a Phase 2 clinical trial for Multiple System Atrophy (MSA). The company also has a drug discovery platform for neurological diseases and is based in Melbourne, Australia, and San Francisco, California.
Investor and Media Contacts:
Australia: Ana Luiza Harrop, we-aualteritytherapeutics@we-worldwide.com, +61 452 510 255
U.S.: Remy Bernarda, remy.bernarda@iradvisory.com, +1 (415) 203-6386
Source: Alterity Therapeutics
